These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [The place of estramustine in the treatment of prostate cancer]. Pintér O, Tóth C, Szabó Z, Lipták J, Fél P, Papp G, Holman E, Hazay L, Streit B, Kisbenedek L, Fehér M, Kocsis I. Orv Hetil; 2005 Mar 20; 146(12):553-7. PubMed ID: 15853064 [Abstract] [Full Text] [Related]
3. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. Zaky Ahel M, Kovacic K, Kraljic I, Tarle M. Anticancer Res; 2001 Mar 20; 21(2B):1475-9. PubMed ID: 11396235 [Abstract] [Full Text] [Related]
4. Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. Mackler NJ, Dunn RL, Hellerstedt B, Cooney KA, Fardig J, Olson K, Pienta KJ, Smith DC. Cancer; 2006 Jun 15; 106(12):2617-23. PubMed ID: 16691618 [Abstract] [Full Text] [Related]
6. Dramatic decline in prostate-specific antigen by withdrawal of estramustine phosphate in hormone refractory prostate cancer. Kobayashi M, Kuramoto H, Ota J, Fujimoto N. Int J Urol; 2006 Jul 15; 13(7):1019-21. PubMed ID: 16882080 [Abstract] [Full Text] [Related]
11. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer. Amato RJ, Hernandez-McClain J, Henary H. Am J Clin Oncol; 2008 Dec 15; 31(6):532-8. PubMed ID: 19060583 [Abstract] [Full Text] [Related]
12. [Prostate-specific antigen as an evaluation method in the treatment of hormone-refractory cancer of the prostate]. Morote J, Lorente JA, Vallejo C, Encabo G, López-Pacios MA, De Torres JA, Soler Rosello A. Actas Urol Esp; 1994 Jun 15; 18(6):656-9. PubMed ID: 7524278 [Abstract] [Full Text] [Related]
13. A retrospective review of combination chemohormonal therapy as initial treatment for locally advanced or metastatic adenocarcinoma of the prostate. Amato RJ, Teh BS, Henary H, Khan M, Saxena S. Urol Oncol; 2009 Jun 15; 27(2):165-9. PubMed ID: 18367115 [Abstract] [Full Text] [Related]
14. [Value of estramustine phosphate in the treatment of estrogen-resistant prostatic adenocarcinoma]. Toulouse J, Jung JL, Bittard M. J Urol (Paris); 1984 Jun 15; 90(1):27-33. PubMed ID: 6725973 [Abstract] [Full Text] [Related]
15. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens. Thall PF, Logothetis C, Pagliaro LC, Wen S, Brown MA, Williams D, Millikan RE. J Natl Cancer Inst; 2007 Nov 07; 99(21):1613-22. PubMed ID: 17971530 [Abstract] [Full Text] [Related]
18. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria. Banu E, Banu A, Medioni J, Levy E, Thiounn N, Mejean A, Andrieu JM, Oudard S. Prostate; 2007 Oct 01; 67(14):1543-9. PubMed ID: 17705243 [Abstract] [Full Text] [Related]